A highly sensitive and specific laboratory test enables the early diagnosis of rheumatoid arthritis (RA), which in turn allows for successful treatment of this autoimmune disease.
The new Anti-CCP hs (high sensitive) test is the most recent development in the area of anticitrullinated peptide antibody (ACPA) testing. This innovative enzyme immunoassay combines the advantages of mutated citrullinated vimentin (MCV) antibody detection (anti-MCV), with the power of modern peptide synthesis. It an effective tool for the rapid and precise routine diagnosis of suspected RA and the diagnosis of early rheumatoid arthritis.
In combination with medical history, clinical observations, and imaging techniques, serological tests like Anti-CCP hs are the basis for early diagnosis of RA. Early diagnosis is critical to patient outcomes because early, effective treatment can avert damage to the joints and maintain their function.
Orgentec Diagnostika (Mainz, Germany) developed the Anti-CCP hs test; it also develops and markets test systems for autoimmune diagnostics and serological tests for infectious disease. Orgentec has developed numerous highly specific ELISA test systems, immunoblot and immunofluorescence tests, the Alegria random access analyzer, and the rheumachec rapid test.